European regulators on Thursday detailed their skepticism of data behind Amgen's rare disease drug Tavneos, explaining a decision last week to pull the drug from the market there.
In new documents ...
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.